Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Syneos Health appoints Michael Brooks as chief development officer » 08:18
07/14/21
07/14
08:18
07/14/21
08:18
SYNH

Syneos Health

$90.22 /

-0.97 (-1.06%)

, LH

LabCorp

$279.78 /

-1.51 (-0.54%)

Syneos Health (SYNH)…

Syneos Health (SYNH) announced the appointment of Michael Brooks to the newly created role of Chief Development Officer. In this role, Brooks will help drive Syneos Health's growth strategy, building a broader, proactive go-to-market ecosystem. Leading the company's Customer Engagement and Market Development portfolio, he'll advance innovation and the voice of the customer across the product development continuum to create better outcomes for patients worldwide. Prior to Syneos Health, Michael was President & Global Head of LabCorp (LH) Clinical Development & Commercialization Services, responsible for phase I-IV services, FSPx services, clinical pharmacology/phase I units, global service delivery hubs in China and India, and commercial services.

ShowHide Related Items >><<
SYNH Syneos Health
$90.22 /

-0.97 (-1.06%)

LH LabCorp
$279.78 /

-1.51 (-0.54%)

SYNH Syneos Health
$90.22 /

-0.97 (-1.06%)

07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
LH LabCorp
$279.78 /

-1.51 (-0.54%)

05/20/21 Argus
LabCorp price target raised to $295 from $270 at Argus
05/18/21 Wells Fargo
Amazon could have interest in diagnostics beyond COVID, says Wells Fargo
05/12/21 Mizuho
LabCorp price target raised to $310 from $267 at Mizuho
05/03/21 William Blair
LabCorp's Vectra deal likely not the last for this year, says William Blair
SYNH Syneos Health
$90.22 /

-0.97 (-1.06%)

LH LabCorp
$279.78 /

-1.51 (-0.54%)

  • 03
    Jun
  • 04
    May
  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
SYNH Syneos Health
$90.22 /

-0.97 (-1.06%)

LH LabCorp
$279.78 /

-1.51 (-0.54%)

LH LabCorp
$279.78 /

-1.51 (-0.54%)

LH LabCorp
$279.78 /

-1.51 (-0.54%)

Recommendations
Syneos Health price target raised to $102 from $90 at Barclays » 07:00
07/13/21
07/13
07:00
07/13/21
07:00
SYNH

Syneos Health

$91.19 /

+0.14 (+0.15%)

Barclays analyst Luke…

Barclays analyst Luke Sergott raised the firm's price target on Syneos Health to $102 from $90 and keeps an Equal Weight rating on the shares. The analyst believes Q2 results for life science tools and diagnostics companies could look a lot like Q1, with "strong beats but mixed results from a stock perspective." The analyst remains favorable on the group.

ShowHide Related Items >><<
SYNH Syneos Health
$91.19 /

+0.14 (+0.15%)

SYNH Syneos Health
$91.19 /

+0.14 (+0.15%)

06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
SYNH Syneos Health
$91.19 /

+0.14 (+0.15%)

  • 03
    Jun
  • 04
    May
  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
SYNH Syneos Health
$91.19 /

+0.14 (+0.15%)

Over a month ago
Conference/Events
Jefferies pharma services analyst holds analyst/industry conference call » 10:25
06/29/21
06/29
10:25
06/29/21
10:25
IQV

Iqvia

$244.90 /

+1.42 (+0.58%)

, ICLR

Icon

$213.24 /

-2.2 (-1.02%)

, SYNH

Syneos Health

$88.64 /

+0.3 (+0.34%)

, PPD

PPD

$46.19 /

+0.02 (+0.04%)

, PRAH

PRA Health

$167.89 /

-0.72 (-0.43%)

, MEDP

Medpace

$181.37 /

-0.52 (-0.29%)

Pharmaceutical Services,…

Pharmaceutical Services, along with John Reites, a Quintiles tech veteran turned digital health CEO of Thread, discuss evolving decentralized trial (DCT) trends, prevalence and forms, impact on trial budgets and speed on an Analyst/Industry conference call to be held on June 29 at 11 am. Webcast Link

ShowHide Related Items >><<
SYNH Syneos Health
$88.64 /

+0.3 (+0.34%)

PRAH PRA Health
$167.89 /

-0.72 (-0.43%)

PPD PPD
$46.19 /

+0.02 (+0.04%)

IQV Iqvia
$244.90 /

+1.42 (+0.58%)

ICLR Icon
$213.24 /

-2.2 (-1.02%)

IQV Iqvia
$244.90 /

+1.42 (+0.58%)

05/14/21 KeyBanc
Iqvia price target raised to $260 from $255 at KeyBanc
05/12/21 Argus
Iqvia price target raised to $260 from $220 at Argus
04/26/21 Truist
Iqvia price target raised to $260 from $235 at Truist
04/26/21 Barclays
Iqvia price target raised to $260 from $235 at Barclays
ICLR Icon
$213.24 /

-2.2 (-1.02%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
05/03/21 Mizuho
Icon price target raised to $242 from $217 at Mizuho
04/29/21 Credit Suisse
Icon price target raised to $245 from $240 at Credit Suisse
04/20/21 Baird
PRA Health downgraded to Neutral from Outperform at Baird
SYNH Syneos Health
$88.64 /

+0.3 (+0.34%)

06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
PPD PPD
$46.19 /

+0.02 (+0.04%)

04/28/21 JPMorgan
PPD downgraded to Neutral from Overweight at JPMorgan
04/20/21 Jefferies
PPD downgraded to Hold from Buy at Jefferies
04/19/21
Fly Intel: Top five analyst downgrades
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
PRAH PRA Health
$167.89 /

-0.72 (-0.43%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
04/29/21 Credit Suisse
PRA Health price target raised to $169 from $159 at Credit Suisse
MEDP Medpace
$181.37 /

-0.52 (-0.29%)

02/17/21 Truist
Medpace price target raised to $180 from $135 at Truist
02/16/21 Credit Suisse
Medpace price target raised to $178 from $155 at Credit Suisse
10/02/20 Truist
Medpace upgraded to Buy from Hold at Truist
07/29/20 Truist
Medpace price target raised to $124 from $95 at SunTrust
SYNH Syneos Health
$88.64 /

+0.3 (+0.34%)

PRAH PRA Health
$167.89 /

-0.72 (-0.43%)

PPD PPD
$46.19 /

+0.02 (+0.04%)

MEDP Medpace
$181.37 /

-0.52 (-0.29%)

IQV Iqvia
$244.90 /

+1.42 (+0.58%)

ICLR Icon
$213.24 /

-2.2 (-1.02%)

  • 03
    Jun
  • 04
    May
  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
  • 17
    Sep
PPD PPD
$46.19 /

+0.02 (+0.04%)

ICLR Icon
$213.24 /

-2.2 (-1.02%)

PPD PPD
$46.19 /

+0.02 (+0.04%)

IQV Iqvia
$244.90 /

+1.42 (+0.58%)

ICLR Icon
$213.24 /

-2.2 (-1.02%)

IQV Iqvia
$244.90 /

+1.42 (+0.58%)

Conference/Events
Jefferies pharma services analyst holds analyst/industry conference call » 04:55
06/29/21
06/29
04:55
06/29/21
04:55
IQV

Iqvia

$243.34 /

-1.94 (-0.79%)

, ICLR

Icon

$215.44 /

-2.26 (-1.04%)

, SYNH

Syneos Health

$88.34 /

-0.505 (-0.57%)

, PPD

PPD

$46.17 /

+0.07 (+0.15%)

, PRAH

PRA Health

$168.61 /

-0.9 (-0.53%)

, MEDP

Medpace

$181.51 /

+1.11 (+0.62%)

Pharmaceutical Services,…

Pharmaceutical Services, along with John Reites, a Quintiles tech veteran turned digital health CEO of Thread, discuss evolving decentralized trial (DCT) trends, prevalence and forms, impact on trial budgets and speed on an Analyst/Industry conference call to be held on June 29 at 11 am. Webcast Link

ShowHide Related Items >><<
SYNH Syneos Health
$88.34 /

-0.505 (-0.57%)

PRAH PRA Health
$168.61 /

-0.9 (-0.53%)

PPD PPD
$46.17 /

+0.07 (+0.15%)

IQV Iqvia
$243.34 /

-1.94 (-0.79%)

ICLR Icon
$215.44 /

-2.26 (-1.04%)

IQV Iqvia
$243.34 /

-1.94 (-0.79%)

05/14/21 KeyBanc
Iqvia price target raised to $260 from $255 at KeyBanc
05/12/21 Argus
Iqvia price target raised to $260 from $220 at Argus
04/26/21 Truist
Iqvia price target raised to $260 from $235 at Truist
04/26/21 Barclays
Iqvia price target raised to $260 from $235 at Barclays
ICLR Icon
$215.44 /

-2.26 (-1.04%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
05/03/21 Mizuho
Icon price target raised to $242 from $217 at Mizuho
04/29/21 Credit Suisse
Icon price target raised to $245 from $240 at Credit Suisse
04/20/21 Baird
PRA Health downgraded to Neutral from Outperform at Baird
SYNH Syneos Health
$88.34 /

-0.505 (-0.57%)

06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
PPD PPD
$46.17 /

+0.07 (+0.15%)

04/28/21 JPMorgan
PPD downgraded to Neutral from Overweight at JPMorgan
04/20/21 Jefferies
PPD downgraded to Hold from Buy at Jefferies
04/19/21
Fly Intel: Top five analyst downgrades
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
PRAH PRA Health
$168.61 /

-0.9 (-0.53%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
04/29/21 Credit Suisse
PRA Health price target raised to $169 from $159 at Credit Suisse
MEDP Medpace
$181.51 /

+1.11 (+0.62%)

02/17/21 Truist
Medpace price target raised to $180 from $135 at Truist
02/16/21 Credit Suisse
Medpace price target raised to $178 from $155 at Credit Suisse
10/02/20 Truist
Medpace upgraded to Buy from Hold at Truist
07/29/20 Truist
Medpace price target raised to $124 from $95 at SunTrust
SYNH Syneos Health
$88.34 /

-0.505 (-0.57%)

PRAH PRA Health
$168.61 /

-0.9 (-0.53%)

PPD PPD
$46.17 /

+0.07 (+0.15%)

MEDP Medpace
$181.51 /

+1.11 (+0.62%)

IQV Iqvia
$243.34 /

-1.94 (-0.79%)

ICLR Icon
$215.44 /

-2.26 (-1.04%)

  • 03
    Jun
  • 04
    May
  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
  • 17
    Sep
PPD PPD
$46.17 /

+0.07 (+0.15%)

ICLR Icon
$215.44 /

-2.26 (-1.04%)

PPD PPD
$46.17 /

+0.07 (+0.15%)

IQV Iqvia
$243.34 /

-1.94 (-0.79%)

ICLR Icon
$215.44 /

-2.26 (-1.04%)

IQV Iqvia
$243.34 /

-1.94 (-0.79%)

Conference/Events
Jefferies pharma services analyst holds analyst/industry conference call » 15:32
06/28/21
06/28
15:32
06/28/21
15:32
IQV

Iqvia

$243.92 /

-1.36 (-0.55%)

, ICLR

Icon

$215.98 /

-1.72 (-0.79%)

, SYNH

Syneos Health

$88.33 /

-0.515 (-0.58%)

, PPD

PPD

$46.17 /

+0.07 (+0.15%)

, PRAH

PRA Health

$168.66 /

-0.85 (-0.50%)

, MEDP

Medpace

$180.95 /

+0.55 (+0.30%)

Pharmaceutical Services,…

Pharmaceutical Services, along with John Reites, a Quintiles tech veteran turned digital health CEO of Thread, discuss evolving decentralized trial (DCT) trends, prevalence and forms, impact on trial budgets and speed on an Analyst/Industry conference call to be held on June 29 at 11 am. Webcast Link

ShowHide Related Items >><<
SYNH Syneos Health
$88.33 /

-0.515 (-0.58%)

PRAH PRA Health
$168.66 /

-0.85 (-0.50%)

PPD PPD
$46.17 /

+0.07 (+0.15%)

IQV Iqvia
$243.92 /

-1.36 (-0.55%)

ICLR Icon
$215.98 /

-1.72 (-0.79%)

IQV Iqvia
$243.92 /

-1.36 (-0.55%)

05/14/21 KeyBanc
Iqvia price target raised to $260 from $255 at KeyBanc
05/12/21 Argus
Iqvia price target raised to $260 from $220 at Argus
04/26/21 Truist
Iqvia price target raised to $260 from $235 at Truist
04/26/21 Barclays
Iqvia price target raised to $260 from $235 at Barclays
ICLR Icon
$215.98 /

-1.72 (-0.79%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
05/03/21 Mizuho
Icon price target raised to $242 from $217 at Mizuho
04/29/21 Credit Suisse
Icon price target raised to $245 from $240 at Credit Suisse
04/20/21 Baird
PRA Health downgraded to Neutral from Outperform at Baird
SYNH Syneos Health
$88.33 /

-0.515 (-0.58%)

06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
PPD PPD
$46.17 /

+0.07 (+0.15%)

04/28/21 JPMorgan
PPD downgraded to Neutral from Overweight at JPMorgan
04/20/21 Jefferies
PPD downgraded to Hold from Buy at Jefferies
04/19/21
Fly Intel: Top five analyst downgrades
04/19/21 Citi
PPD downgraded to Neutral from Buy at Citi
PRAH PRA Health
$168.66 /

-0.85 (-0.50%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
04/29/21 Credit Suisse
PRA Health price target raised to $169 from $159 at Credit Suisse
MEDP Medpace
$180.95 /

+0.55 (+0.30%)

02/17/21 Truist
Medpace price target raised to $180 from $135 at Truist
02/16/21 Credit Suisse
Medpace price target raised to $178 from $155 at Credit Suisse
10/02/20 Truist
Medpace upgraded to Buy from Hold at Truist
07/29/20 Truist
Medpace price target raised to $124 from $95 at SunTrust
SYNH Syneos Health
$88.33 /

-0.515 (-0.58%)

PRAH PRA Health
$168.66 /

-0.85 (-0.50%)

PPD PPD
$46.17 /

+0.07 (+0.15%)

MEDP Medpace
$180.95 /

+0.55 (+0.30%)

IQV Iqvia
$243.92 /

-1.36 (-0.55%)

ICLR Icon
$215.98 /

-1.72 (-0.79%)

  • 03
    Jun
  • 04
    May
  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
  • 17
    Sep
PPD PPD
$46.17 /

+0.07 (+0.15%)

ICLR Icon
$215.98 /

-1.72 (-0.79%)

PPD PPD
$46.17 /

+0.07 (+0.15%)

IQV Iqvia
$243.92 /

-1.36 (-0.55%)

ICLR Icon
$215.98 /

-1.72 (-0.79%)

IQV Iqvia
$243.92 /

-1.36 (-0.55%)

Hot Stocks
Syneos Health accelerates decentralized clinical trial delivery » 08:45
06/21/21
06/21
08:45
06/21/21
08:45
SYNH

Syneos Health

$84.72 /

-0.7 (-0.82%)

Syneos Health expanded…

Syneos Health expanded its Decentralized Clinical Trial capabilities to include a dedicated Decentralized Clinical Trials Site Advocacy Group, continuing the momentum for Decentralized Solutions demonstrated by the recent acquisition of Illingworth Research Group to move clinical trials closer to the patient. Decentralized Solutions from Syneos Health combines deep insights, agile technologies, innovative trial design experience and operational excellence - transforming product development. This novel, industry-leading Decentralized Clinical Trials Site Advocacy initiative takes decentralized methodologies and technologies to the next level, actively listening to find the right solutions. The Group will engage with sites and community stakeholders including patients, advocacy groups, industry, academic centers and sponsors, securing valuable insights across the clinical to commercial spectrum - from the mobile research nursing solutions provided by Illingworth Research Group to new and innovative mobile, digital and telemedicine capabilities - to better inform decentralized protocol design, data capture and patient retention strategies. The Group will pressure-test, problem-solve and co-create innovative decentralized clinical trial methodologies. The Group will also accelerate insights to enhance decentralized clinical trial implementation by driving an ongoing discussion about how to incorporate new technologies, making clinical trials more accessible to patients to facilitate better and more efficient solutions. This includes using mobile research, optimized digital health technologies and direct-to-patient logistics. Syneos Health deploys a Dynamic Assembly strategy, partnering with an open ecosystem of preferred best-of-breed data and technology collaborators to address decentralized study nuances.

ShowHide Related Items >><<
SYNH Syneos Health
$84.72 /

-0.7 (-0.82%)

SYNH Syneos Health
$84.72 /

-0.7 (-0.82%)

06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
SYNH Syneos Health
$84.72 /

-0.7 (-0.82%)

  • 03
    Jun
  • 04
    May
  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
SYNH Syneos Health
$84.72 /

-0.7 (-0.82%)

Syndicate
Syneos Health announces offering of 10.85M shares of common stock for holders » 16:07
06/02/21
06/02
16:07
06/02/21
16:07
SYNH

Syneos Health

$85.53 /

-1.94 (-2.22%)

Syneos Health announced…

Syneos Health announced it commenced an underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 10.85M shares of the company's common stock pursuant to the company's shelf registration statement filed with the SEC. In addition, Syneos Health entered into an agreement with the selling stockholders to repurchase an aggregate of 500K shares of common stock from such selling stockholders in a private transaction, concurrently with the closing of the offering, at the price at which the shares of common stock are sold to the public in the offering, less underwriting discounts and commissions. BofA Securities is acting as the sole underwriter of the Offering.

ShowHide Related Items >><<
SYNH Syneos Health
$85.53 /

-1.94 (-2.22%)

SYNH Syneos Health
$85.53 /

-1.94 (-2.22%)

06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
SYNH Syneos Health
$85.53 /

-1.94 (-2.22%)

  • 04
    May
  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
SYNH Syneos Health
$85.53 /

-1.94 (-2.22%)

Recommendations
Syneos Health price target raised to $104 from $88 at Truist » 09:15
06/02/21
06/02
09:15
06/02/21
09:15
SYNH

Syneos Health

$87.47 /

-0.53 (-0.60%)

Truist analyst Sandy…

Truist analyst Sandy Draper raised the firm's price target on Syneos Health to $104 from $88 and keeps a Buy rating on the shares. The analyst is updating his model after the company's Q1 results reported in April with a new forward earnings multiple of 18-times vs. 16-times prior. Draper adds that as Syneos' execution improves, there is room for further multiple expansion since the stock currently trades at a 400bps discount to its peer group.

ShowHide Related Items >><<
SYNH Syneos Health
$87.47 /

-0.53 (-0.60%)

SYNH Syneos Health
$87.47 /

-0.53 (-0.60%)

04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
02/22/21 Mizuho
Syneos Health price target raised to $87 from $72 at Mizuho
SYNH Syneos Health
$87.47 /

-0.53 (-0.60%)

  • 04
    May
  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
SYNH Syneos Health
$87.47 /

-0.53 (-0.60%)

Syndicate
Syneos Health 7M share Spot Secondary priced at $81.60 » 07:59
05/04/21
05/04
07:59
05/04/21
07:59
SYNH

Syneos Health

/

+

The deal priced below the…

The deal priced below the last closing price of $83.35. BofA is acting as sole book running manager for the offering.

ShowHide Related Items >><<
SYNH Syneos Health
/

+

SYNH Syneos Health
/

+

04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
02/22/21 Mizuho
Syneos Health price target raised to $87 from $72 at Mizuho
SYNH Syneos Health
/

+

  • 04
    May
  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
SYNH Syneos Health
/

+

Syndicate
Syneos Health files to sell 7M shares of common stock for holders  16:41
05/03/21
05/03
16:41
05/03/21
16:41
SYNH

Syneos Health

$83.30 /

-1.56 (-1.84%)

 
ShowHide Related Items >><<
SYNH Syneos Health
$83.30 /

-1.56 (-1.84%)

SYNH Syneos Health
$83.30 /

-1.56 (-1.84%)

04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
03/02/21 Barclays
Syneos Health initiated with an Equal Weight at Barclays
02/22/21 Mizuho
Syneos Health price target raised to $87 from $72 at Mizuho
SYNH Syneos Health
$83.30 /

-1.56 (-1.84%)

  • 01
    Mar
  • 02
    Dec
  • 16
    Sep
SYNH Syneos Health
$83.30 /

-1.56 (-1.84%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.